Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer

Prostate Cancer and Prostatic Diseases volume 8, pages 260–265 (2005)Cite this article

Abstract

The enzymes thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), and orotate phosphoribosyl transferase (OPRT) are involved in the metabolism of the anticancer drug 5-fluorouracil. No reports have examined the expression of these enzymes in prostate cancer (CaP). A total of 25 previously untreated, hormone-sensitive CaP tissue samples and 11 benign prostatic hyperplasia (BPH) specimens were examined. Tissue of CaP and BPH tissue samples were obtained from formalin-fixed, paraffin-embedded sections by laser-captured microdissection, and then RNA was extracted. mRNA expression of TS, DPD, TP, and OPRT was analyzed by quantitative reverse transcriptase-polymerase chain reaction. TS and OPRT expression levels were significantly higher in CaP samples than in BPH. DPD expression level in poorly differentiated CaP was significantly lower than that in CaP with more favorable—well or moderately differentiated—histopathology.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Parker SL, Tong T, Bolden S, Wingo PA . Cancer statistics, 1997. CA Cancer J Clin 1997; 47: 5–27.

    Article  CAS  Google Scholar 

  2. Oh WK, Kantoff PW . Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998; 160: 1220–1229.

    Article  CAS  Google Scholar 

  3. Kubota Y et al. Do the worst histological elements in needle biopsy specimens of prostate cancer predict prognosis? Lancet 1996; 348: 822–823.

    Article  CAS  Google Scholar 

  4. Longley DB, Harkin DP, Johnston PG . 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330–338.

    Article  CAS  Google Scholar 

  5. Droz JP et al. Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol 2003; 14: 1291–1298.

    Article  CAS  Google Scholar 

  6. Shinohara N et al. 5-Fluorouracil and low-dose recombinant interferon-alpha-2a in patients with hormone-refractory adenocarcinoma of the prostate. Prostate 1998; 35: 56–62.

    Article  CAS  Google Scholar 

  7. Danenberg PV . Thymidylate synthetase—a target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977; 473: 73–92.

    CAS  PubMed  Google Scholar 

  8. Santi DV, McHenry CS, Sommer H . Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974; 13: 471–481.

    Article  CAS  Google Scholar 

  9. Johnston PG, Drake JC, Trepel J, Allegra CJ . Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 1992; 52: 4306–4312.

    CAS  PubMed  Google Scholar 

  10. Johnston PG et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 2640–2647.

    Article  CAS  Google Scholar 

  11. Pestalozzi BC et al. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 1997; 15: 1923–1931.

    Article  CAS  Google Scholar 

  12. Shintani Y et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 2003; 104: 790–795.

    Article  CAS  Google Scholar 

  13. Mizutani Y et al. Significance of thymidylate synthase activity in renal cell carcinoma. Clin Cancer Res 2003; 9: 1453–1460.

    CAS  PubMed  Google Scholar 

  14. Foekens JA et al. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res 2001; 61: 1421–1425.

    CAS  Google Scholar 

  15. Kuniyasu T, Nakamura T, Tabuchi Y, Kuroda Y . Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. Cancer 1998; 83: 1300–1306.

    Article  CAS  Google Scholar 

  16. Johnston PG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407–1412.

    CAS  PubMed  Google Scholar 

  17. Fraile RJ et al. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980; 40: 2223–2228.

    CAS  PubMed  Google Scholar 

  18. Diasio RB, Harris BE . Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215–237.

    Article  CAS  Google Scholar 

  19. Jiang W, Lu Z, He Y, Diasio RB . Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 1997; 3: 395–399.

    CAS  PubMed  Google Scholar 

  20. Etienne MC et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663–1670.

    Article  CAS  Google Scholar 

  21. Mizutani Y et al. The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. Eur J Cancer 2001; 37: 569–575.

    Article  CAS  Google Scholar 

  22. Ichikawa W et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003; 89: 1486–1492.

    Article  CAS  Google Scholar 

  23. Mizutani Y et al. Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. Cancer 2004; 100: 723–731.

    Article  CAS  Google Scholar 

  24. Mizutani Y et al. Significance of orotate phosphoribosyltransferase activity in renal cell carcinoma. J Urol 2004; 171: 605–610.

    Article  CAS  Google Scholar 

  25. Ishikawa F et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989; 338: 557–562.

    Article  CAS  Google Scholar 

  26. Lord RV et al. Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000; 4: 135–142.

    Article  CAS  Google Scholar 

  27. Heid CA, Stevens J, Livak KJ, Williams PM . Real time quantitative PCR. Genome Res 1996; 6: 986–994.

    Article  CAS  Google Scholar 

  28. Gibson UE, Heid CA, Williams PM . A novel method for real time quantitative RT-PCR. Genome Res 1996; 6: 995–1001.

    Article  CAS  Google Scholar 

  29. General Rule for Clinical and Pathological Studies on Prostate Cancer, 3rd edn. Japanese Urological Association, The Japanese Society of Pathology: Kanehara, Tokyo, 2001.

  30. Ishikawa T et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998; 58: 685–690.

    CAS  PubMed  Google Scholar 

  31. Terashima M et al. Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur J Cancer 2002; 38: 2375–2381.

    Article  CAS  Google Scholar 

  32. Ishikawa Y et al. Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res 1999; 19: 5635–5640.

    CAS  Google Scholar 

  33. Johnson MR et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999; 5: 2006–2011.

    CAS  PubMed  Google Scholar 

  34. Takabayashi A et al. Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy. Int J Oncol 2000; 17: 889–895.

    CAS  PubMed  Google Scholar 

  35. Horiguchi J et al. Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer. Br J Cancer 2002; 86: 222–225.

    Article  CAS  Google Scholar 

  36. Nakagawa T et al. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur+Uracil) in patients with p-stage I nonsmall-cell lung cancer. J Surg Oncol 2002, 8187–8192.

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Yokohama City University School of Medicine, Yokohama, Japan

    Y Miyoshi, H Uemura, H Ishiguro & Y Kubota

  2. Department of Pathology, Yokohama City University School of Medicine, Yokohama, Japan

    H Kitamura

  3. Drug Safety Research Laboratory, Taiho Pharmaceutical Co. Ltd, Tokyo, Japan

    N Nomura

  4. Division of Biochemistry and Molecular Biology, University of Southern California/Norris Comprehensive Cancer Center, University of Southern California School of Medicine, Los Angeles, USA

    P V Danenberg

Authors
  1. Y Miyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Uemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Ishiguro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Kitamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P V Danenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y Kubota
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Miyoshi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miyoshi, Y., Uemura, H., Ishiguro, H. et al. Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer. Prostate Cancer Prostatic Dis 8, 260–265 (2005). https://doi.org/10.1038/sj.pcan.4500817

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500817

Keywords

This article is cited by

Search

Advanced search

Quick links